The estimated Net Worth of Anna Ewa Kozicz Stankiewicz is at least $158 Thousand dollars as of 2 April 2020. Mrs. Stankiewicz owns over 490 units of Calyxt Inc stock worth over $19,940 and over the last 6 years she sold CLXT stock worth over $31,787. In addition, she makes $105,983 as Independent Director at Calyxt Inc.
Sign up
Mrs. Stankiewicz CLXT stock SEC Form 4 insiders trading
Anna has made over 5 trades of the Calyxt Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently she sold 490 units of CLXT stock worth $1,857 on 2 April 2020.
The largest trade she's ever made was selling 1,000 units of Calyxt Inc stock on 15 June 2018 worth over $19,490. On average, Anna trades about 272 units every 66 days since 2018. As of 2 April 2020 she still owns at least 3,165 units of Calyxt Inc stock.
You can see the complete history of Mrs. Stankiewicz stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Anna Kozicz-Stankiewicz biography
Anna Ewa Kozicz-Stankiewicz serves as Independent Director of the Company. Mrs. Kozicz has served as a member of our Board since July 2017. Ms. Kozicz received a Bachelor of Arts in Math and Economics from Columbia College and her MBA from Columbia Business School. She started her career in investment banking in 1996 at Credit Suisse First Boston in its Financial Institutions Group before moving to Goldman Sachs in 2000 where she held multiple positions, including Managing Director, and spent most of her time in the Principal Strategies Group with a focus on investing in the global agricultural sector. She moved to Caxton Associates in 2009 to work as an equity Portfolio Manager before moving to BlackRock in 2012 where she held management roles as Head of US Strategy and Corporate Development as well as investing roles as Portfolio Manager of a private assets portfolio for ABR Reinsurance Ltd., a Bermuda based reinsurance company which Ms. Kozicz helped to set up on behalf of BlackRock. During her time at Goldman Sachs, she served as a director on the board of a New York-based federal credit union Polish & Slavic Federal Credit Union. In July 2017, she left BlackRock and partnered with Cowen Investment Management to create a new investment fund focused on sustainability in agriculture, energy and transportation services. Based on her investment experience in the agriculture industry, we believe Ms. Kozicz has the appropriate set of skills to serve as a member of our Board.
What is the salary of Anna Stankiewicz?
As the Independent Director of Calyxt Inc, the total compensation of Anna Stankiewicz at Calyxt Inc is $105,983. There are 10 executives at Calyxt Inc getting paid more, with James Blome having the highest compensation of $4,488,350.
How old is Anna Stankiewicz?
Anna Stankiewicz is 45, she's been the Independent Director of Calyxt Inc since 2017. There are 11 older and 4 younger executives at Calyxt Inc. The oldest executive at Calyxt Inc is Philippe Dumont, 68, who is the Independent Director.
What's Anna Stankiewicz's mailing address?
Anna's mailing address filed with the SEC is Mount Ridge Road, Roseville, Ramsey County, Minnesota, 55113-5499, United States.
Insiders trading at Calyxt Inc
Over the last 7 years, insiders at Calyxt Inc have traded over $2,578,214 worth of Calyxt Inc stock and bought 116,475 units worth $1,447,167 . The most active insiders traders include Kimberly K. Nelson, Daniel F Voytas, and Yves J Ribeill. On average, Calyxt Inc executives and independent directors trade stock every 23 days with the average trade being worth of $35,853. The most recent stock trade was executed by Yves J Ribeill on 19 September 2022, trading 30,000 units of CLXT stock currently worth $7,200.
What does Calyxt Inc's logo look like?
Complete history of Mrs. Stankiewicz stock trades at Calyxt Inc
Calyxt Inc executives and stock owners
Calyxt Inc executives and other stock owners filed with the SEC include:
-
James Blome,
Chief Executive Officer, Director -
William Koschak,
Chief Financial Officer -
Debra Frimerman,
General Counsel -
Kimberly Nelson,
Independent Director -
William F. Koschak,
Chief Financial Officer -
Dr. Travis J. Frey Ph.D.,
Chief Technology Officer -
Daniel Voytas,
Chief Scientific Officer -
Philippe Dumont,
Independent Director -
Yves Ribeill,
Chairman of the Board -
Christopher Neugent,
Independent Director -
Anna Kozicz-Stankiewicz,
Independent Director -
Jonathan Fassberg,
Independent Director -
Chris Tyson,
IR Contact Officer -
Laurent Arthaud,
Director -
Bobby Williams,
Director - Gene Editing -
Vince Restucci,
Vice President of Agronomy Services -
Sarah Reiter,
Vice President - Business Development -
Travis Frey,
Chief Technology Officer -
Keith Blanks,
Senior Vice President of Sales and Marketing -
Gerry Nuovo,
Sr. VP of Bus. Devel. -
Dr. Stephen M. Bravo,
Chief Medical Officer -
Trina Lundblad,
Director of Communications -
Debra H. Frimerman,
Gen. Counsel & Corp. Sec. -
Dr. Daniel F. Voytas Ph.D.,
Founder, Chief Science Officer & Chair of Scientific Advisory Board -
Michael Allen Carr,
Pres, CEO & Director -
Michael A. Carr,
President and CEO -
Manoj Sahoo,
Chief Commercial Officer -
Alain Godard,
Director -
Bryan W.J. Corkal,
Chief Financial Officer -
Michel Arbadji,
Director of Business Developme -
Federico A. Tripodi,
Chief Executive Officer -
Glenn R Bowers,
Vice President of Breeding -
S.A. Cellectis,
10% owner